อาจารย์ ดร.ภก.

นเรนทร์ฤทธิ์ กรุณา

Lecturer

narainrit karuna

หน่วยงาน
ภาควิชาบริบาลเภสัชกรรม
อีเมล
narainrit.k@cmu.ac.th ,banknarainrit@gmail.com
การศึกษา
  • 2559, เภสัชศาสตรบัณฑิต (เกียรตินิยมอันดับสอง)
    มหาวิทยาลัยเชียงใหม่
  • 2562, Master of Science (International Program) เภสัชกรรมคลินิก
    มหาวิทยาลัยมหิดล
  • 2567, Doctor of Philosophy Medicine
    Queen’s University Belfast,United Kingdom

งานวิจัย

Google Scholar

Scopus

ข้อมูลจาก Google Scholar

  • 0, Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand
    Pharmacogenetics and genomics 30 (4), 73-80, 2020
  • 0, Phytochemical Characterization and Anticancer Activity of Clerodendrum chinense Leaf Extract Against Breast and Cervical Cancer Cells
    International Journal of Molecular Sciences 26 (6), 2729, 2025
  • 0, Proteomic-based biomarker discovery reveals panels of diagnostic biomarkers for early identification of heart failure subtypes
    Journal of Translational Medicine 23 (1), 546, 2025
  • 0, Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
    Cardiovascular diabetology 24 (1), 206, 2025
  • 0, Proteome Alterations in Cardiac Fibroblasts: Insights from Experimental Myocardial Infarction and Clinical Ischaemic Cardiomyopathy
    International Journal of Molecular Sciences 26 (8), 3846, 2025
  • 0, Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy
    Diabetes/Metabolism Research and Reviews 41 (6), e70081, 2025
  • 0, Deep phenotyping of a modified diabetic cardiomyopathy mouse model which reflects clinical disease progression
    Diabetology & Metabolic Syndrome 17 (1), 334, 2025
  • 0, Signature of diabetic cardiomyopathy progression using high-fat diet and streptozotocin mouse model: from subclinical to clinical with three-hit mouse model
    European Heart Journal 45 (Supplement_1), ehae666. 3781, 2024
  • 0, 3 Neprilysin inhibition modulates extracellular matrix proteins in a pre-heart failure population with diabetes: sub-analysis of the parable trial
    Heart 110 (Suppl 6), A1-A2, 2024
  • 0, 8 From oncology to cardiology: repurposing a cancer drug for treatment of heart failure–clinical and preclinical evidence
    Heart 110 (Suppl 6), A5-A5, 2024
  • 0, 40 Characterising diabetic cardiomyopathy progression with longitudinal echocardiography and cellular profiling of cardiac tissue identifies an opportunity for immunomodulatory …
    Heart 110 (Suppl 6), A39-A40, 2024
  • 0, 28 Identification of biomarker proteins associated with myocardial damage
    Heart 110 (Suppl 6), A29-A29, 2024
  • 0, Progression of diabetic cardiomyopathy exhibits alterations in cardiac function andstructure and macrophages composition
    Medical Sciences Forum 27 (3), 1.2, 2024
  • 0, Abstracts of the 2023 Autumn Meeting of the British Society for Cardiovascular Research
    Medical Sciences Forum 27 (1), 3, 2024
  • 0, Protection with LCZ696 (sacubitril/valsartan) against diastolic dysfunction and cardiac fibrosis in high-fat diet/streptozotocin mouse model
    Medical Sciences Forum 27 (2), 1.4, 2024
  • 0, Abstracts of the 2022 Autumn Meeting of the British Society for Cardiovascular Research
    Medical Sciences Forum 27 (1), 2, 2024
  • 0, BS47 Endothelial colony-forming cell NOX4 signalling promotes vasoreparative capacity of coronary microvascular endothelial cells and reduces adverse cardiac remodelling
    Heart 110 (Suppl 3), A276-A277, 2024
  • 0, BS08 ISG15 signalling promotes coronary microvascular endothelial dysfunction in experimental diabetes
    Heart 110 (Suppl 3), A249-A249, 2024
  • 0, Entresto as a novel radioprotectant in a partial heart irradiation mouse model
    Radiotherapy and Oncology 194 (Supplement 1), S5273-S5275, 2024
  • 0, Single-nuclei sequencing of diabetic cardiomyopathy mouse reveals extent of immune activation and modulated by sacubitril/valsartan
    Heart Failure 2023 and the World Congress on Acute Heart Failure, 20 - 23 …, 2023